Essential phospholipids use in the treatment of drug-induced liver injury in pregnant women

Cover Page


Cite item

Full Text

Abstract

The aim of the study was evaluation the efficiency of essential phospholipids for the treatment of drug-induced liver disease in pregnant women. In the research group included 67 pregnant women with clinical and biochemical manifestations of drug-induced cytolytic syndrome, 58 pregnant women (the main group) were treated with hepatoprotectors, 9 women (the control group) the treatment of essential phospholipids wasn’t carried out. Patients of both groups were eliminated hormonal drugs and other drugs or their dosage is reduced as much as possible. Drug liver disease in pregnancy is manifested by increased transaminase, in some cases accompanied by increased level of gamma glutamyl transpeptidase, liver glutamate dehydrogenase. Against the background of the treatment in both groups decrease in transaminases have been reported. But the rate of decline of aminotransferases was differed, so in the main group decrease of ALT and AST was occurred faster than in the control group.

About the authors

Liudmila K Palgova

St Petersburg State University

Author for correspondence.
Email: l_palgova@mail.ru

Professor, scientific and educational center of Gastroenterology and Hepatology

Russian Federation, Saint Petersburg, Russia

Irina V Borisova

FSBSI “The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott”

Email: irena_irbis@mail.ru

graduate student

Russian Federation, Saint Petersburg, Russia

Natalia V Zhestkova

FSBSI “The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott”

Email: Zhestkova@me.com

Head of Outpatient Department

Russian Federation, Saint Petersburg, Russia

Marina A Tarasova

FSBSI “The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott”

Email: tarasova@ott.ru

MD, PhD, professor

Russian Federation, Saint Petersburg, Russia

References

  1. World Health Organization (WHO). The Use of the WHO-UMC System for Standardised Case Causality Assessment. WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database 2000. [Электронный ресурс]. Available from: http://who-umc.org/Graphics/24734.pdf.1.
  2. Leise MD. Drug-induced liver injury. Mayo Clin Proc. 2014;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016.
  3. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73-96. doi: 10.1016/S1089-3261(05) 70097-0.
  4. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Acute Liver Failure Study Group. Hepatol. 2005;42(6):1364-6. doi: 10.1002/hep.20948.
  5. Reporting adverse drug reactions definitions of terms and criteria for their use. Geneva: CIOMS; 1999.
  6. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a Clinical Research Workshop. Hepatol. 2010;52(2):730-42. doi: 10.1002/hep.23696.
  7. Aithal GP, Watkins PB, Andrade RJ, et al. Review. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15. doi: 10.1038/clpt.2011.58.
  8. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury Network (DILIN) prospective study. Rationale, design and conduct. Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005.
  9. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatol. 2003;37(4):924-30. doi: 10.1053/jhep.2003.50144.
  10. Ивашкин B.T., Золотаревский В.Б., Маевская М.В., и др. Болезни печени и желчевыводящих путей. – М., 2002. [Ivashkin BT, Zolotarevskiy VB, Maevskaya MV, et al. Bolezni pecheni i zhelchevyivodyaschih putey. Moscow; 2002. (In Russ.)]
  11. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001;14(6):611-50. doi: 10.1021/tx0002583.
  12. William M. Drug-Induced Hepatotoxicity. N Engl J Med. 2003;349(5):474-85. doi: 10.1056/NEJMra021844.
  13. Галимова С.Ф. Лекарственные поражения печени // РЖГГК. – 2012. – № 3. – С. 38–48. [Galimova SF. Lekarstvennye porazhenija pecheni. RZhGGK. 2012;(3):38-48. (In Russ.)]
  14. Feghali MN, Mattison DR. Clinical therapeutics in pregnancy. J Biomed Biotechnol. 2011:783528. doi: 10.1155/2011/783528.
  15. Успенская Ю.Б., Кузнецова И.В., Гончаренко Н.В., Суханова Г.А. Функциональное нарушение печени в первой половине беременности // Врач. – 2013. – № 12. – С. 70–73 [Uspenskaja JuB, Kuznecova IV, Goncharenko NV, Suhanova GA. Funkcional’noe narushenie pecheni v pervoj polovine beremennosti. Vrach. 2013;(12):70-73. (In Russ.)]
  16. Kopylov U, Avidan B, Papageorgiou N, et al. Idiopathic liver function test abnormality in pregnancy is associated with assisted reproduction techniques. Fertil Steril. 2013;99:377-81. doi: 10.1016/j.fertnstert.2012.09.015.
  17. Еремина Е.Ю. Лекарственный гепатит у беременных // Врач. – 2015. – № 8. – C. 11–13. [Eremina EJu. Lekarstvennyj gepatit u beremennyh. Vrach. 2015;(8):11-3. (In Russ.)]
  18. Mei-Dan E, Wiznitzer A, Sergienko R, et al. Prediction of preeclampsia: liver function tests during the first 20 gestational weeks. J Matern Fetal Neonatal Med. 2013;26(3):250-253. doi: 10.3109/14767058.2012. 733771.
  19. Danan G. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323-30. doi: 10.1016/0895-4356(93)90101-6.
  20. Danan G. Causality assessment of drug-induced liver injury. J Hepatol. 1988;7(1):132-6. doi: 10.1002/hep.23577.
  21. Danan G. RUCAM in drug and herb induced liver injury: The Update. Int J Mol Sci. 2016;17(1):14. doi: 10.3390/ijms17010014.
  22. Stirnimann G. Liver injury caused by drugs: an update. Swiss Med Wkly. 2010;140:13080. doi: 10.4414/smw.2010.13080.
  23. Ивашкин В.Т., Широкова Е.Н., Маевская М.В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза // РЖГГК. – 2015. – Т. 25. – № 2. – С. 41–57. [Ivashkin VT, Shirokova EN, Maevskaya MV, et al. Klinicheskie rekomendatsii Rossiyskoy gastroenterologicheskoy assotsiatsii i Rossiyskogo obschestva po izucheniyu pecheni po diagnostike i lecheniyu holestaza. RZhGGK. 2015;25(2):41. (In Russ.)]
  24. Ларионова В.Б., Громова Е.Г., Снеговой А.В. Клинические рекомендации по коррекции гепатотоксичности индуцированной противоопухолевой химиотерапии. – М., 2014 [Электронный ресурс]. Available from: http://oncology association.ru/docs/recomend/may 2015/09 vz-rek.pdf [Larionova VB, Gromova EG, Snegovoj AV. Klinicheskie rekomendacii po korrekcii gepatotoksichnosti inducirovannoj protivoopuholevoj himioterapii. Moscow; 2014. (In Russ.)]
  25. Мордык А.В., Иванова О.Г., Нагибина Л.А., и др. Лекарственные поражения печени и их лечение в клинике туберкулеза // Туберкулез и болезни легких. – 2015. – № 9. – С. 47–52. [Mordyik AV, Ivanova OG, Nagibina LA, et al. Lekarstvennyie porazheniya pecheni i ih lechenie v klinike tuberkuleza. Tuberkulez i bolezni legkih. 2015;(9):47-52. (In Russ.)]
  26. Zhao D, Liu G. Protective effect of bicyclol on concanavalin A-induced liver nuclear DNA injury in mice. Zhonghua Yi XueZaZhi. 2001;81(14):844-8.
  27. Sakakima Y, Hayakawa A, et al. Prevention of hepatocarcinogenesis with phosphatidylcholine and menaquinone-4: in vitro and in vivo experiments. J Hepatol. 2007;47(1):83-92. doi: 10.1016/j.jhep.2007.01.030.
  28. Ушкалова Е.А. Место эссенциальных фосфолипидов в современной медицине // Фарматека. – 2003. – № 10. [Ushkalova EA. Mesto essentsialnyih fosfolipidov v sovremennoy meditsine. Farmateka. 2003;(10). (In Russ.)]
  29. Бацков С.С., Гордиенко А.В. Лекарственные поражения печени: учебное пособие для слушателей. – СПб.: ВМедА, 2002 [Batskov SS, Gordienko AV. Lekarstvennyie porazheniya pecheni: ucheb. posobie dlya slushateley. Saint Petersburg: VMedA; 2002. (In Russ.)]
  30. Калачнюк Т.Н. Оценка тяжести течения и эффективности терапии лекарственных гепатитов: автореф. дис. … канд. мед. наук. – М., 2011. [Kalachnyuk TN. Otsenka tyazhesti techeniya i effektivnosti terapii lekarstvennyih gepatitov. [dissertation] Moscow; 2011. (In Russ.)]
  31. Скрипник И.Н. Эссенциальные фосфолипиды в лечении и профилактике медикаментозных поражений печени // Сучас. гастроентерологія. – 2009. – № 4. – C. 22–31 [Skripnik IN. Essentsialnyie fosfolipidyi v lechenii i profilaktike medikamentoznyih porazheniy pecheni. Suchas gastroenterologIya. 2009;(4):22-31. (In Russ.)]
  32. Ессауленко Е.Е. Гепатопротекторные свойства и метаболические эффекты липофильных продуктов растительного происхождения в эксперименте: Дис. … д-ра биол. наук. – Краснодар, 2014. [Essaulenko EE. Gepatoprotektornyie svoystva i metabolicheskie effektyi lipofilnyih produktov rastitelnogo proishozhdeniya v eksperimente [dissertation]. Krasnodar; 2014. (In Russ.)]
  33. Рзаева Р.Н., Мозговая Е.В., Пальгова Л.К. Стеатоз печени у женщин с ожирением. Особенности течения беременности // Журнал акушерства и женских болезней. – 2014. – № 6. – С. 55–65. [Rzaeva RN, Mozgovaya EV, Palgova LK. Liver steatosis at women with obesity. The features of pregnancy. Journal of Obstetrics and Women’s Diseases. 2014;(6):55-65. (In Russ.)]
  34. Рзаева Р.Н., Мозговая Е.В., Пальгова Л.К., и др. Особенности течения беременности у женщин при стеатозе печени и ожирении // Журнал акушерства и женских болезней. – 2013. – № 6. – С. 47–54. [Rzaeva RN, Mozgovaya EV, Palgova LK, et al. The features of pregnancy at women with liver steatosis and obesity. Journal of Obstetrics and Women’s Diseases. 2013;(6):47–54. (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Palgova L.K., Borisova I.V., Zhestkova N.V., Tarasova M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies